Trial Profile
A phase 2, randomized, double-blind, multicenter, dose-exploration study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 09 Oct 2020 This trial is completed in Ireland, according to European Clinical Trials Database record.
- 26 Apr 2012 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Actual initiation date changed from Aug 2006 to Apr 2006 as reported by ClinicalTrials.gov.